Our study aims to investigate the concentration of SDF-1α in the serum of elderly AML patients compared to that in healthy individuals, analyze its correlation with chemotherapy outcomes, and observe the fluctuations in serum SDF-1α levels before and after chemotherapy. This evidence concerns the gene CXCL12 and acute myeloid leukemia.